» Articles » PMID: 36794663

Bone Marrow Mesenchymal Stem Cell-derived Exosomal MiR-30e-5p Ameliorates High-glucose Induced Renal Proximal Tubular Cell Pyroptosis by Inhibiting ELAVL1

Overview
Journal Ren Fail
Publisher Informa Healthcare
Date 2023 Feb 16
PMID 36794663
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The rapid increase in the prevalence of diabetes has resulted in more cases of diabetic kidney disease (DKD). Treatment with bone marrow mesenchymal stem cells (BMSCs) may represent an alternative strategy to manage DKD.

Methods: HK-2 cells were treated with 30 mM high glucose (HG). Bone marrow MSC-derived exosomes (BMSC-exos) were isolated and internalized into HK-2 cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) and lactate dehydrogenase (LDH) assays were used to measure viability and cytotoxicity. The secretion of IL-1β and IL-18 was measured by ELISA. Pyroptosis was assessed by flow cytometry. Quantitative RT-PCR was used to measure the levels of miR-30e-5p, ELAV like RNA binding protein 1 (ELAVL1), IL-1β, and IL-18. The expression of ELAVL1 and pyroptosis-associated cytokine proteins was determined by western blot analysis. A dual-luciferase reporter gene assay was conducted to confirm the relationship between miR-30e-5p and ELAVL1.

Results: BMSC-exos decreased LDH, IL-1β, and IL-18 secretion and inhibited the expression of the pyroptosis-related factors (IL-1β, caspase-1, GSDMD-N, and NLRP3) in HG-induced HK-2 cells. Moreover, miR-30e-5p depletion derived from BMSC-exos promoted HK-2 cell pyroptosis. Besides, miR-30e-5p over-expression or ELVAL1 knockdown could directly inhibit pyroptosis. ELAVL1 was a target of miR-30e-5p and knocking down ELAVL1 reversed the effect of miR-30e-5p inhibition in BMSC-exos-treated HK-2 cells.

Conclusions: BMSC-derived exosomal miR-30e-5p inhibits caspase-1-mediated pyroptosis by targeting ELAVL1 in HG-induced HK-2 cells, which might provide a new strategy for treating DKD.

Citing Articles

Pyroptosis: candidate key targets for mesenchymal stem cell-derived exosomes for the treatment of bone-related diseases.

Li H, Zhang P, Lin M, Li K, Zhang C, He X Stem Cell Res Ther. 2025; 16(1):68.

PMID: 39940049 PMC: 11816542. DOI: 10.1186/s13287-025-04167-y.


DNA damage-induced AIM2 pyroptosis in high glucose-induced proximal tubular epithelial cell.

Li L, Zhang L, Cai Y, Li J, Zheng S, Wang W Front Cell Dev Biol. 2024; 12:1457369.

PMID: 39659523 PMC: 11628503. DOI: 10.3389/fcell.2024.1457369.


The role of intercellular communication in diabetic nephropathy.

Wang B, Xiong Y, Deng X, Wang Y, Gong S, Yang S Front Immunol. 2024; 15:1423784.

PMID: 39238645 PMC: 11374600. DOI: 10.3389/fimmu.2024.1423784.


Role of Extracellular Vesicle-Derived Noncoding RNAs in Diabetic Kidney Disease.

Hu M, Shen X, Zhou L Kidney Dis (Basel). 2024; 10(4):303-312.

PMID: 39131883 PMC: 11309761. DOI: 10.1159/000539024.


Research progress on the role of extracellular vesicles in the pathogenesis of diabetic kidney disease.

Jin J, Zhang M Ren Fail. 2024; 46(1):2352629.

PMID: 38769599 PMC: 11107856. DOI: 10.1080/0886022X.2024.2352629.


References
1.
Zhang H, Wang Z . Effect and Regulation of the NLRP3 Inflammasome During Renal Fibrosis. Front Cell Dev Biol. 2020; 7:379. PMC: 6992891. DOI: 10.3389/fcell.2019.00379. View

2.
Laudato S, Patil N, Abba M, Leupold J, Benner A, Gaiser T . P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017; 141(9):1879-1890. DOI: 10.1002/ijc.30854. View

3.
Lin J, Cheng A, Cheng K, Deng Q, Zhang S, Lan Z . New Insights into the Mechanisms of Pyroptosis and Implications for Diabetic Kidney Disease. Int J Mol Sci. 2020; 21(19). PMC: 7583981. DOI: 10.3390/ijms21197057. View

4.
Chen D, Liu Y, Chen J, Lin H, Guo H, Wu Y . JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. Eur J Pharmacol. 2021; 902:174121. DOI: 10.1016/j.ejphar.2021.174121. View

5.
Mao J, Hu X, Pang P, Zhou B, Li D, Shan H . miR-30e acts as a tumor suppressor in hepatocellular carcinoma partly via JAK1/STAT3 pathway. Oncol Rep. 2017; 38(1):393-401. DOI: 10.3892/or.2017.5683. View